Abstract:Abstract Study question Does co-administration of GnRH agonist and Human chorionic gonadotropin(dual trigger) in PGT cycles improve the number of usable blastocysts per patient compared to hCG alone? Summary answer Using the dual trigger has no effect on the number of usable blastocysts undergoing the GnRH-ant protocol for PGT compared to triggering with hCG alone. What is known already HCG is used at the end of controlled ovarian hyperstimulation as a surrogate LH surge to induce final oocyte maturation. Recently, based on retrospective studies, the co-administration of GnRH agonist and hCG for final oocyte maturation (dual trigger) has been suggested to improve IVF outcome and pregnancy rates. Study design, size, duration A prospective, randomized, open-label controlled clinical trial (ChiCTR-ICR-2000031342), enrolled patients attending our university affiliated Infertility and IVF center (the Reproductive and Genetic Hospital of CITIC-Xiangya, China) between August 2020 and June 2021. This sample size achieves with a power of 80%, at a significance level(α) of 0.05. A sample size of 160 patients, 80 randomized to each group, was chosen to allow for those 10% dropped out. Participants/materials, setting, methods The inclusion criteria for participating were: women age 20–35years, AMH≥1.2ng/ml and /or AFC ≥5, Couples with PGT-SR preimplantation genetic testing for chromosomal structural rearrangements (patients with abnormal chromosomal structure only in male or female), undergoing one of their first PGT cycle attempts. Patients fulfilled the criteria on the trigger day were randomly assigned to receive hCG or the dual trigger for final oocyte maturation. The primary outcome was the number of usable blastocysts per patient. Main results and the role of chance 160 patients were included in the study. The age (29.1 years versus 29.4 years), BMI (22.1 kg/m2 versus 21.9 kg/m2) and the AMH (5.3 ng/ml versus 5.3 ng/ml) were comparable between the two groups. Based on PP analysis, there were no statistical difference in the number of eggs retrieved (17.1 versus 15.9), the MII oocytes (13.3 versus 12.5), the number of usable blastocysts per patient (5.0 versus 4.6) and top-quality blastocysts per patient (3.4 versus 3.2) between the two groups. Limitations, reasons for caution None Wider implications of the findings The enhanced response observed with the dual trigger might lead to better IVF outcomes were it used more widely. Trial registration number ChiCTR-ICR-2000031342

The Value of HCG Serum Concentrations after Trigger in Predicting Pregnancy and Live Birth Rates in IVF–ICSI

Serum LH Levels on hCG Trigger Day Affect IVF Outcomes Intensified by Poor Ovarian Reserve and Advanced Age

Comparison of Progesterone Measurement on Day Of, and Day After, HCG Administration in IVF–embryo Transfer Cycles

Association Between Luteinizing Hormone Level Decrease on the Triggering Day and Pregnancy Outcome for in Vitro Fertilization/intracytoplasmic Sperm Injection Patients Following Gonadotropin-Releasing Hormone Antagonist Protocol: a Retrospective Cohort Study

Association between LH level decrease on the triggering day and pregnancy outcome for IVF/ICSI patients following GnRH antagonist protocol: a retrospective cohort study

P-676 Comparison of Hcg Triggering Versus Hcg in Combination with a GnRH Agonist: a Prospective Randomized Controlled Trial

The effect of progesterone level prior to oocyte retrieval on the numbers of oocytes retrieved and embryo quality in IVF treatment cycles: an analysis of 2,978 cycles

Recurrent Ivf Failure Is Associated With Elevated Progesterone On The Day Of Hcg Administration

Double Measurements of Serum HCG Concentration and Its Ratio May Predict IVF Outcome.

The Effect of Serum Luteinizing Hormone on Trigger Day with a GnRH Antagonist Protocol in IVF/ICSI Treatment

Evolution of serum progesterone levels in the very early luteal phase of stimulated IVF/ICSI cycles post hCG trigger: a proof of concept study

Low LH Level on the Day of GnRH Agonist Trigger Is Associated With Reduced Ongoing Pregnancy and Live Birth Rates and Increased Early Miscarriage Rates Following IVF/ICSI Treatment and Fresh Embryo Transfer

Serum Progesterone Concentration on Day of HCG Administration and IVF Outcome

Premature Progesterone Rise Positively Correlates with Clinical Pregnancy Rate in In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) Patients with good Ovarian Response

Increased Maternal Serum Hcg Concentrations in the Presence of a Female Fetus As Early As 2 Weeks after IVF-ET.

Association between progesterone level on human chronic gonadotropin (hcg) trigger day and clincal outcomes of cleavage-stage embryos or blastocysts transfer in assisted reproduction technology (art) cycles.

Association Between Serum Estradiol Level on the Human Chorionic Gonadotrophin Administration Day and Clinical Outcome.

THE BENEFICIAL EFFECT FOR LBR OF SERUM LH (5-10IU/L) ON TRIGGER DAY WITH GnRH ANTAGONIST PROTOCOL

Paired Detection of Serum Human Chorionic Gonadotropin Possibly Predicting Pregnant Outcome after in Vitro Fertilization-a Large Scale Retrospective Research

Serum Human Chorionic Gonadotropin Among Women With and Without Obesity After Single Embryo Transfers

Positive Association of the Number of Oocyte Retrieved with the Maternal Hcg Concentration in Early Pregnancy Achieved by Vitrified-Warmed Embryo Transfer after in Vitro Maturation